Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 1;332(13):1105-1107.
doi: 10.1001/jama.2024.15775.

RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older

Diya Surie  1 , Wesley H Self  2 , Yuwei Zhu  3 , Katharine A Yuengling  1 , Cassandra A Johnson  3 , Carlos G Grijalva  4 , Fatimah S Dawood  1 ; Investigating Respiratory Viruses in the Acutely Ill (IVY) Network
Collaborators, Affiliations

RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older

Diya Surie et al. JAMA. .
No abstract available

Plain language summary

This study evaluates the effectiveness of the respiratory syncytial virus vaccine against hospitalization for acute respiratory illness among US adults aged 60 years and older.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Self reported receiving grants from the US Centers for Disease Control and Prevention (CDC) to their institution for salary support during the conduct of the study. Dr Zhu reported receiving grants from the CDC during the conduct of the study. Dr Grijalva reported a contract from the CDC during the conduct of the study; contracts from the US Food and Drug Administration and Syneos Health; and grants from the National Institutes of Health and Agency for Healthcare Research and Quality outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Vaccine Effectiveness Against Respiratory Syncytial Virus (RSV)–Associated Hospitalization Among Adults 60 Years and Older
aMultivariable logistic regression compared the odds of RSV vaccination among RSV case and control patients. Models were adjusted for a base set of a priori variables, including age, sex, race and ethnicity, US Department of Health and Human Services Region, and calendar month of admission. Vaccine effectiveness (VE) was computed as: (1 − adjusted odds ratio) × 100%. bPropensity for vaccination was modeled with an expanded set of a priori covariates. Weights were computed as the inverse of the probability of vaccination. The standardized differences for covariates after weighting were all <0.1, except for Social Vulnerability Index, which was included in the final logistic regression model that compared the odds of RSV vaccination between RSV case and control patients (eMethods in Supplement 1).
See this image and copyright information in PMC

References

    1. Melgar M, Britton A, Roper LE, et al. Use of respiratory syncytial virus vaccines in older adults. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801. doi: 10.15585/mmwr.mm7229a4 - DOI - PMC - PubMed
    1. Walsh EE, Pérez Marc G, Zareba AM, et al. ; RENOIR Clinical Trial Group . Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465-1477. doi: 10.1056/NEJMoa2213836 - DOI - PubMed
    1. Papi A, Ison MG, Langley JM, et al. ; AReSVi-006 Study Group . Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595-608. doi: 10.1056/NEJMoa2209604 - DOI - PubMed
    1. Surie D, Yuengling KA, DeCuir J, et al. ; Investigating Respiratory Viruses in the Acutely Ill (IVY) Network . Severity of respiratory syncytial virus vs COVID-19 and influenza among hospitalized US adults. JAMA Netw Open. 2024;7(4):e244954. doi: 10.1001/jamanetworkopen.2024.4954 - DOI - PMC - PubMed
    1. Havers FP, Whitaker M, Melgar M, et al. ; RSV-NET Surveillance Team . Characteristics and outcomes among adults aged ≥60 years hospitalized with laboratory-confirmed respiratory syncytial virus. MMWR Morb Mortal Wkly Rep. 2023;72(40):1075-1082. - PMC - PubMed

Publication types

MeSH terms

Substances